BEM-101

BEM-101 is a preclinical-stage multi-target drug candidate developed by Shanghai Benemae Pharmaceutical (also known as Renhui Biology) for the treatment of metabolic diseases. The drug is part of Benemae's pipeline focusing on complex metabolic pathways, utilizing their expertise in recombinant protein and peptide engineering. Although the specific molecular targets (such as GLP-1, GIP, or Glucagon receptors) have not been explicitly confirmed in public disclosures, the "multi-target" designation suggests a poly-agonist approach intended to provide enhanced efficacy in conditions like obesity or type 2 diabetes compared to single-target therapies. It is currently undergoing preclinical evaluation to address the multi-factorial mechanisms underlying metabolic disorders.